Navigation Links
Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Date:9/10/2007

horts. Patients will be immunized every 28 days for a period of 8 weeks (3 administrations). Post-treatment evaluations will begin four weeks after the last of the three injections. Patients enrolled with high-grade CIN (CIN 2/3) disease will be eligible to undergo clinically appropriate treatment of the cervix at the twelfth week of the study.

Nventa will also collect immunological data from these patients that may provide an early indication of potential efficacy of the compound. To determine if HspE7 plus adjuvant elicit T-cell and B-cell specific HPV-E7 immune responses, all patients will be typed for class I and II human leukocyte antigen (HLA) subtypes, and will be evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

Conference Call:

----------------

Nventa will hold a conference call on Thursday, September, 13, 2007, at 9:00 am Eastern Time (6:00 am Pacific Time) to allow securities analysts and shareholders the opportunity to hear Management discuss an update on the progress with HspE7 and other important milestones.

Live Participant Dial In Numbers:

---------------------------------

If you are in the U.S. or Canada call (Toll Free): 877 407-8031. If you

are International call: 201 689-8031.

Replay of Audio Portion:

------------------------

A replay of this call will be available at 12:00 noon Eastern Time from

September 13 through 11:59 pm Eastern Time on September 20, 2007. The

playback number (Toll Free): 877-660-6853 (North America) or 201 612-

7415 (International), Account Number: 286; Conference Identification

Number: 254756 (both required for playback).

Webcast:

--------

Nventa will also webcast its investor call on Thursday, September 13,

2007, at 9:00 am Eastern Time (6:00 am Pacific Time). The call is being

webcast by Vcall and can be accessed through Nventa's
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... Stockholders Approve Board Authority to Implement Reverse Stock Split and ... of Total Shares and Authorized Shares, NEW HAVEN, Conn., ... that a Special Meeting of,Stockholders was held at the Omni ... At the meeting, shareholders voted to approve amendments to the,Company,s ...
... - For Full Year 2007, Strong Operating Earnings and Tax Benefits Drive ... and Product Sales Both Grow 14% -, - In 2008, Gen-Probe Expects ... Driving Anticipated EPS of ... GPRO ) today reported strong financial results for the fourth,quarter and ...
... DENVER, Feb. 13 Rocky Mountain Biosystems, ... announced receipt of a,grant award of approximately ... of Allergy and Infectious Diseases at the ... Self-Administered Vaccination Electromechanical,(SAVE) technology for influenza vaccination. ...
Cached Biology Technology:Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 2Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 4Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 5Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 6Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 7Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 8Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 9Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 10Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 11Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 12Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 13Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 14Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 15Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 16NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... and the Manchester Metropolitan University have carried out the ... amber more than 30 millions years ago. , The ... the Dominican (Caribbean) regions has revealed new insights into ... period. , It is the first time ancient spiders ...
... at the National Institute of Allergy and Infectious Disease ... (NIH), have identified a critical human cell surface molecule ... virus that causes Kaposi's sarcoma and certain forms of ... HIV/AIDS, and it typically manifests as multiple purple-hued skin ...
... the amino acid supplement L-arginine following a heart attack ... may be associated with an increased risk of death, ... of JAMA. , L-arginine is a widely available dietary ... with hypertension, angina, heart failure and sexual dysfunction, according ...
Cached Biology News:Amber reveals ecology of 30 million year old spiders 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 3Little known DNA repair enzyme may be a tumor suppressor gene 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: